Resources

Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company are working together to pave a new pathway for type 2 diabetes patients with the sodium glucose co-transporter 2 (SGLT2) inhibitor, empagliflozin. The investigational agent is currently in Phase III clinical trials focusing on four pivotal trials that have concluded with …

Canagliflozin Added on to Dipeptidyl Peptidase-4 Inhibitors or Glucagon-Like Peptide-1 Agonists With or Without Other Antihyperglycemic Agents in Type 2 Diabetes Mellitus (T2DM)   Canagliflozin is an SGLT2 inhibitor which was intended for treatment in diabetic type 2 patients. This analysis was a post hoc design and data was utilized …

In this week’s set of Homerun Slides, we continue our exploration of workplace wellness: topics covered include Barriers and Opportunities for Implementation of Workplace Wellness, and Measuring Return on Investment (ROI) in Wellness Programs, focusing on both employer and employee benefits….

Christina Kanaka-Gantenbein, MD, PhD Definition of emergency Diabetic ketoacidosis (DKA) is the leading cause of morbidity and mortality in children with Type 1 diabetes mellitus (T1D). Mortality is mainly related to the occurrence of cerebral edema, while only a minority of deaths are attributed to other causes.1,2 …

Men with diabetes develop ED 10 to 15 years earlier than men without diabetes….

Women with type 2 diabetes have distorted microbiota…. 

The collected data could help clarify whether the drugs are contributing to the development of pancreatitis or pancreatic cancer…. 

A protein called NFAT is connected to diabetes and damage to the heart….

Patients might only need to inject once or twice a week…. 

Glucose total AUC was greater in the no-breakfast group compared with the breakfast group….